title: N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs.
abstract: A challenge to successful chemotherapy of visceral leishmaniasis is the dose-limiting toxicity of antileishmanial agents. One approach to increase the efficacy and reduce the toxicity of these agents is to direct the drug to the phagolysosomes of the reticuloendothelial system (RES) where the leishmanial parasites reside. In this work a series of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-antileishmanial drug conjugates containing lysosomally degradable side chains and with or without sugar targeting moieties were synthesized, characterized and investigated for their in vivo efficacy in mice infected with Leishmania. An 8-aminoquinoline analog, namely 8-[(4-amino-1-methylbutyl)amino]-5-[3,4-dichlorophenoxy]-6-methoxy-4-methylquinoline (NPC1161) was used as a model antileishmanial agent. At 5 mg/kg body weight drug equivalent dose, all HPMA copolymer-drug conjugates which contained lysosomally degradable side chains showed significant in vivo antileishmanial activity (>99% inhibition), comparable to the activity of the free drug. At 2 mg dose, the same conjugates were significantly more effective (84-90% inhibition) than the free drug (67% inhibition). These results indicate the potential of lysosomotropic HPMA copolymers for the targeted delivery of antileishmanial compounds in the treatment of visceral leishmaniasis.
authors.affiliation: Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, University, MS 38677, USA.
authors.forename: A
authors.initials: A
authors.lastname: Nan
authors.forename: N P
authors.initials: NP
authors.lastname: Nanayakkara
authors.forename: L A
authors.initials: LA
authors.lastname: Walker
authors.forename: V
authors.initials: V
authors.lastname: Yardley
authors.forename: S L
authors.initials: SL
authors.lastname: Croft
authors.forename: H
authors.initials: H
authors.lastname: Ghandehari
mesh_terms: D000634:Aminoquinolines / Q000008:administration & dosage*; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D006224:Cricetinae; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D007275:Injections, Intravenous; D007893:Leishmania donovani / Q000187:drug effects / Q000302:isolation & purification; D008647:Mesocricetus; D008689:Methacrylates / Q000008:administration & dosage* / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D011108:Polymers / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D000634:Aminoquinolines; D000981:Antiprotozoal Agents; D008689:Methacrylates; D011108:Polymers; C080436:8-aminoquinoline; C032802:hydroxypropyl methacrylate